DAVID ALTSHULER - 19 Jul 2022 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
EVP, Global Research and CSO
Signature
/s/ Joy Liu, Attorney-in-Fact
Issuer symbol
VRTX
Transactions as of
19 Jul 2022
Net transactions value
-$2,059,782
Form type
4
Filing time
21 Jul 2022, 16:48:41 UTC
Previous filing
28 Feb 2022
Next filing
10 Aug 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Options Exercise $1,955,375 +10,427 +29% $187.53 46,604 19 Jul 2022 Direct F1
transaction VRTX Common Stock Options Exercise $1,141,573 +7,338 +16% $155.57 53,942 19 Jul 2022 Direct
transaction VRTX Common Stock Sale $276,111 -963 -1.8% $286.72 52,979 19 Jul 2022 Direct F2, F3, F4
transaction VRTX Common Stock Sale $1,312,793 -4,561 -8.6% $287.83 48,418 19 Jul 2022 Direct F2, F3, F5
transaction VRTX Common Stock Sale $1,656,100 -5,737 -12% $288.67 42,681 19 Jul 2022 Direct F2, F3, F6
transaction VRTX Common Stock Sale $1,911,726 -6,604 -15% $289.48 36,077 19 Jul 2022 Direct F2, F3, F7

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VRTX Stock Option (Right to Buy) Options Exercise $0 -10,427 -73% $0.000000 3,911 19 Jul 2022 Common Stock 10,427 $187.53 Direct F8
transaction VRTX Stock Option (Right to Buy) Options Exercise $0 -7,338 -100% $0.000000* 0 19 Jul 2022 Common Stock 7,338 $155.57 Direct F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 100 shares previously purchased under the issuer's Employee Stock Purchase Plan.
F2 Transaction made pursuant to Mr. Altshuler's company approved trading plan under Rule 10b5-1.
F3 Mr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4 Open market sales reported on this line occurred at a weighted average price of $286.72 (range $286.07 to $287.01).
F5 Open market sales reported on this line occurred at a weighted average price of $287.83 (range $287.11 to $288.10).
F6 Open market sales reported on this line occurred at a weighted average price of $288.67 (range $288.11 to $289.09).
F7 Open market sales reported on this line occurred at a weighted average price of $289.48 (range $289.11 to $290.06).
F8 The option vests in 16 quarterly installments from 2/6/2019.
F9 Fully vested.